(Q37839828)

24 August 2017

1 reference

title

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review (English)

1 reference

24 August 2017

main subject

human papilloma virus

object named as

human papilloma virus

1 reference

1

Daniela Koleva

1 reference

24 August 2017

4

Livio Garattini

1 reference

24 August 2017

3

Anna Padula

1 reference

24 August 2017

Paola De Compadri

2

1 reference

24 August 2017

publication date

11 February 2011

1 reference

Internal and emergency medicine

24 August 2017

published in

1 reference

24 August 2017

volume

6

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

163-174

1 reference

The causal relation between human papillomavirus and cervical cancer

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Efficacy and other milestones for human papillomavirus vaccine introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

The current and future role of screening in the era of HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Cervical cancer screening policies and coverage in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

HPV and cervical cancer: screening or vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Cost-effectiveness analyses of human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Model for assessing human papillomavirus vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

The natural history of cervical HPV infection: unresolved issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Utilities of the EQ-5D: transferable or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Bias in published cost effectiveness studies: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

Sheep and goats: separating cervix and corpus uteri from imprecisely coded uterine cancer deaths, for studies of geographical and temporal variations in mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0529-3

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

21 January 2018

1 reference

12 December 2020

Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria

1 reference

12 December 2020

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

1 reference

12 December 2020

Human Papillomavirus Vaccination — Reasons for Caution

1 reference

12 December 2020

Should boys receive the human papillomavirus vaccine? No

1 reference

12 December 2020

Stage-specific treatment costs for cervical cancer in the United Kingdom

1 reference

12 December 2020

Economic evaluation of human papillomavirus vaccination in the United Kingdom

1 reference

12 December 2020

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

1 reference

12 December 2020

Management of low-grade cervical abnormalities detected at screening: which method do women prefer?

1 reference

12 December 2020

Health and economic impact associated with a quadrivalent HPV vaccine in Italy

1 reference

12 December 2020

Projected cost-effectiveness of new vaccines for adolescents in the United States

1 reference

12 December 2020

Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands

1 reference

12 December 2020

Controlling cervical cancer

1 reference

12 December 2020

The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy

1 reference

12 December 2020

HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness

1 reference

12 December 2020

10.1007/S11739-011-0529-3

Identifiers

DOI

1 reference

24 August 2017

1 reference